Market Performance - The new stock index and the near-term new stock index fell by 2.01% and 2.23% respectively during the first week of February 2026[7] - The market experienced significant adjustments, with the technology sector leading the decline, particularly in the non-ferrous metals and electronic sectors[7] New Stock Listings - The first unprofitable new stock of the year, Beixin Life, was listed, achieving an average first-day increase of 185.65%[1] - Two new stocks contributed to A1/A2/B class investors' single-account full returns of 17.80/9.44/7.90 thousand yuan, enhancing the yield rates for 500 million scale accounts by 0.36‰/0.19‰/0.16‰[41] Trading Activity - Trading activity in the new stock sector continued to decline, with turnover rates for the new stock index and near-term new stock index dropping by 2.10 percentage points and 2.25 percentage points respectively[21] - The net active selling in the new stock sector was 2.936 billion yuan, a decrease of 3.540 billion yuan from the previous week[23] Valuation Changes - The new stock index PE (TTM) increased by 1.76, while the near-term new stock index PE (TTM) decreased by 23.73[14] - The latest PE (TTM) values for the new stock index and near-term new stock index were 80.0X and 159.7X, corresponding to historical percentile levels of 83.8% and 99.2% respectively[14] Upcoming Unlocks - In the second week of February, three new stocks are expected to unlock, with a total unlock scale of 254 million yuan, maintaining low levels[35]

Core Viewpoint - Zhendemedical has experienced a consecutive two-day trading limit increase, indicating strong market interest and potential investor confidence [1] Group 1: Stock Performance - Zhendemedical's stock reached a trading limit at 9:58 AM with a transaction volume of 453 million yuan and a turnover rate of 1.96% [1] Group 2: Corporate Governance and Strategy - The company is optimizing its corporate governance structure by introducing a stock ownership plan for core employees and establishing a mechanism for repurchasing and canceling unblocked shares, which is expected to enhance team stability [1] - Zhendemedical is also engaging in hedging activities to mitigate risks associated with raw material price fluctuations, ensuring stable production costs [1] Group 3: Industry Context - Other companies within the pharmaceutical sector are showing positive performance due to improved governance and stable business operations, contributing to a sector-wide synergy effect [1]

Core Viewpoint - Aikang Medical (01789) shares rose over 5%, currently up 5.29% at HKD 6.17, with a trading volume of HKD 20.71 million [1] Group 1: Company Developments - Aikang Medical announced on February 9 that it has secured six bids from December 2024 to January 2026, involving its self-developed K3 robot system, K3+ robot system, Visual Treatment Solution, and a digital orthopedic full-process solution [1] - The total bid value for four of the projects amounts to RMB 23.54 million, while the remaining two bids have not yet disclosed their values [1] - Among the six projects, one bid for Shandong Provincial Hospital is valued at RMB 4.46 million, expected to recognize revenue in 2026, with two bids awarded this year from Zhejiang University School of Medicine First Affiliated Hospital and a hospital in Shandong [1]

Core Viewpoint - Aikang Medical (01789) has seen a stock price increase of over 5%, currently trading at 6.17 HKD with a transaction volume of 20.71 million HKD, following the announcement of six successful bids for various medical systems and solutions [1] Group 1: Company Developments - Aikang Medical announced on February 9 that it has secured six bids from December 2024 to January 2026, which include its self-developed K3 robot system, K3+ robot system, Visual Treatment Solution, and a comprehensive digital orthopedic solution [1] - The total bid amount for four of these projects is 23.54 million RMB, while the amounts for the remaining two bids have yet to be disclosed [1] - One of the notable projects includes a bid for Shandong Provincial Hospital, valued at 4.46 million RMB, expected to recognize revenue in 2026 [1] Group 2: Market Response - Following the announcement, Aikang Medical's stock price rose by 5.29%, indicating positive market sentiment towards the company's recent achievements [1] - The trading volume reached 20.71 million HKD, reflecting increased investor interest in the company's future prospects [1]

【中信证券海外策略】 12026年1月29日至2月4日EPFR跟踪的全球资金整体流入发达市场及新兴市场分别为251.65/88.27亿美元。 全球主动资金流入中国市场约7.03亿美元。 全球主动资金流入中国市场约7.03亿美元。 分不同区域主动资金情况看，本周欧洲区域资金流入规模最大，为0.7亿美元。 分行业看，本周中国资产各板块均呈流入趋势，其中信息技术、金融和可选消费板块流入规模最大，分别为 0.94/0.79/0.63亿美元。 2我们测算，2026年1月26日至1月30日，港股通/外资中介/内资中介分别净流入18/113/-118亿港元。 南向资金边际流入游戏、电池、医疗器械等板块；而外资增持黄金、半导体、造纸等板块。 互联网、保险、地产、多元金融、建材获南向及外资的共同青睐。 分不同区域主动资金情况看，本周欧洲区域资金流入规模最大，为0.7亿美元。 分行业看，本周中国资产各板块均呈流入趋势，其中信息技术、金融和可选消费板块流入规模最大，分别为 0.94/0.79/0 【中信证券海外策略】 12026年1月29日至2月4日EPFR跟踪的全球资金整体流入发达市场及新兴市场分别为251.65/88.27亿美 ...

中证智能财讯 惠泰医疗（688617）2月10日公告，基于对公司未来发展前景的信心及长期投资价值的认 可，为增强投资者信心并建立健全长效激励机制，公司计划以自有资金通过集中竞价交易方式回购部分 股份，回购资金总额不低于1.5亿元且不超过2亿元，回购价格上限为315元/股，回购期限为董事会审议 通过之日起10个月内。本次回购股份将在未来适宜时机用于员工持股计划或股权激励。公司股票2月9日 收盘价为229.38元/股。 2025年前三季度，公司实现营业总收入18.67亿元，同比增长22.47%；归母净利润6.23亿元，同比增长 18.02%。 核校：孙萍 按回购价格上限测算，预计回购股份数量为47.62万股至63.49万股，占公司总股本的0.34%至0.45%。公 司表示，本次回购不会对公司的日常经营、财务、研发和未来发展产生重大影响，公司有能力支付回购 价款。若回购股份未能在三年内转让完毕，将依法予以注销。 惠泰医疗是一家专注于电生理和介入类医疗器械的研发、生产和销售的高新技术企业，已形成了以完整 冠脉通路和心脏电生理医疗器械为主导，外周血管和非血管介入医疗器械为重点发展方向的业务布局。 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news highlights the financial performance and stock trading activities of Jianerkang, indicating a decrease in both revenue and net profit for the year 2025 [2][3] - As of February 9, Jianerkang's stock price increased by 0.18%, with a trading volume of 23.71 million yuan, and a net financing buy of -2.36 million yuan [1] - The company has a total financing and securities lending balance of 57.98 million yuan, with the financing balance accounting for 4.91% of the circulating market value, which is below the 10% percentile level over the past year [1] Group 2 - Jianerkang's main business includes the research, production, and sales of medical dressings and disposable medical devices, with revenue composition as follows: nursing products 33.19%, surgical consumables 30.64%, polymer and auxiliary products 18.46%, disinfecting and cleaning products 16.93%, and others 0.79% [1] - As of September 30, the number of shareholders for Jianerkang was 17,100, a decrease of 6.15% from the previous period, while the average circulating shares per person increased by 38.51% [2] - For the period from January to September 2025, Jianerkang reported a revenue of 725 million yuan, a year-on-year decrease of 7.35%, and a net profit attributable to the parent company of 76.41 million yuan, down 18.24% year-on-year [2]

Group 1: Emerging Technologies and Standards - The approval of national standards for emerging fields includes brain-computer interfaces and digital twins, which clarify reference frameworks and data formats to support high-quality development in cutting-edge technology [1] - A total of 47 national standards were released for new materials, including aluminum nitride single crystal polishing wafers and carbon fiber reinforced composites, aimed at fostering innovation in the new materials industry [1] Group 2: Transportation and Logistics - Two national standards for intelligent connected vehicles were published, focusing on performance testing for autonomous driving and parking systems, enhancing the performance and safety of intelligent connected vehicles [1] - Six national standards related to automotive components, such as door handles and adaptive cruise control systems, were introduced to improve road traffic safety and environmental sustainability [1] - Two mandatory national standards for the postal industry were released, addressing safety production operations and equipment configuration for postal and express delivery services, thereby enhancing safety governance in the postal sector [1] Group 3: Environmental Protection - Six national standards were established for ecological protection, including general requirements for natural protected area signage and drone inspection technology for forest and grassland fire prevention, providing standard support for national ecological security [2] - Two national standards for environmental due diligence assessments and environmental report verification were published, which are significant for promoting green development and improving environmental governance efficiency [2] - Two national standards related to greenhouse gas emission accounting and reporting requirements were released, aiding companies in accurately calculating and reporting their greenhouse gas emissions [2] Group 4: Safety Production - Sixteen mandatory national standards in the fire safety sector were updated, including outdoor fire hydrants and combustible gas detectors, providing technical guidelines to mitigate major fire safety risks [2] - Fourteen national standards for special equipment, such as gantry cranes and pressure vessels, were published to ensure the safe and stable operation of these devices [2] Group 5: Public Welfare and Healthcare - Four national standards for services for people with disabilities were released, including standards for single-arm walking aids and autism rehabilitation institutions, aimed at improving the quality of rehabilitation aids and services for vulnerable groups [2] - Eight national standards were established for medical laboratories and medical device sterilization processes, regulating practices in medical experiments and manufacturing [2] Group 6: Additional Standards - The market regulatory authority also published national standards related to transportation terminology, earth-moving machinery, and reciprocating internal combustion engines [3]

2月9日，爱迪特涨0.76%，成交额8219.79万元。两融数据显示，当日爱迪特获融资买入额660.33万元， 融资偿还813.53万元，融资净买入-153.20万元。截至2月9日，爱迪特融资融券余额合计1.16亿元。 融资方面，爱迪特当日融资买入660.33万元。当前融资余额1.15亿元，占流通市值的3.11%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，爱迪特2月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量2300.00股，融券余额11.87万元，超过近一年90%分位水平，处于高位。 资料显示，爱迪特(秦皇岛)科技股份有限公司位于河北省秦皇岛市经济技术开发区都山路9号，成立日 期2007年3月15日，上市日期2024年6月26日，公司主营业务涉及自主研发、生产、销售具有国际竞争力 的氧化锆瓷块等口腔修复材料。主营业务收入构成为：口腔修复材料73.74%，口腔数字化设备 19.80%，其他产品及服务6.46%。 截至9月30日，爱迪特股东户数9851.00，较上期增加4.66%；人均流通股7310股，较上期减少4.46%。 2025年1月-9月 ...